Financial Data and Key Metrics Changes - R&D expenses decreased to approximately $2.4 million in Q3 2025 from $3.7 million in Q3 2024, primarily due to reductions in clinical trial support and consulting expenses [35] - General and administrative expenses increased to approximately $1.9 million in Q3 2025 from $1.5 million in the prior year, attributed to higher business development and investor relations costs [35] - The net loss for Q3 2025 was approximately $4.2 million, or $0.39 per share, compared to a net loss of approximately $4.5 million, or $0.42 per share in Q3 2024 [36] Business Line Data and Key Metrics Changes - The LP-184 phase 1a clinical trial achieved a 48% clinical benefit rate in evaluable cancer patients, validating the AI-driven precision medicine approach [5][11] - Preliminary phase II data from the LP-300 Harmonic trial showed an 86% clinical benefit rate, with one patient demonstrating a durable complete response for nearly two years [20][21] - The LP-284 program targeting recurrent non-Hodgkin's lymphoma generated interest from biopharma companies, showcasing a complete metabolic response in a heavily pretreated patient [23] Market Data and Key Metrics Changes - The combined annual market potential for the targeted indications of LP-184 exceeds $7 billion, with specific opportunities in triple-negative breast cancer, non-small cell lung cancer, bladder cancer, and recurrent GBM [17] - The market opportunity for the LP-300 program in lung cancer among never-smokers is approaching $4 billion annually, with no current approved therapies for this demographic [19] - The LP-284 program has a global market opportunity of about $3 billion, focusing on patients with aggressive recurrent non-Hodgkin's lymphoma [22] Company Strategy and Development Direction - The company is focused on integrating AI and machine learning into drug discovery and development, positioning itself as a leader in precision oncology [4][39] - The RADR AI platform is being commercialized, with eight distinct AI-powered modules developed to address critical pain points in oncology drug development [26][34] - The introduction of the Zeta platform aims to streamline rare cancer research and drug development, enhancing decision-making and reducing costs [30][32] Management's Comments on Operating Environment and Future Outlook - Management highlighted the transformative nature of the past quarter, achieving significant clinical, regulatory, and validation milestones [5] - The company expects to continue advancing its clinical assets while scaling its AI platform for commercial deployment, emphasizing a dual engine strategy [39][40] - Management expressed confidence in the potential of their AI tools and services to represent several hundred million dollars in standalone market potential [34] Other Important Information - As of September 30, 2025, the company had approximately $12.4 million in cash, cash equivalents, and marketable securities, providing a runway into approximately Q3 2026 [36] - The company entered into an ATM sales agreement to offer and sell up to $15.53 million of its common stock, raising approximately $989,000 during Q3 2025 [37] Q&A Session Summary Question: Update on interim event analysis for the LP-300 trial - Management indicated that they do not expect to reach the 31 events required for analysis until early 2026, which is seen as positive news as it suggests patients are remaining on the trial longer [41] Question: Status of the Denmark trial - The Denmark trial has been approved, with IRBs set and a project manager assigned, expected to start in late December or early January [42] Question: IND submission for the pediatric CNS program - Management confirmed readiness to submit the IND for the pediatric CNS program in the coming weeks [42] Question: Details on the Zeta platform - The Zeta platform is expected to have an interesting and bumpy early rollout, with internal usage already underway and plans for broader rollout in Q1 [43] Question: Indications for LP-184 - Management plans to identify the most impactful indications for larger scale trials, with interest from pharmaceutical companies [44]